Europe Expansion Aeterna Zentaris seeks to commercialize macimorelin beyond the US and Canada, presenting a clear opportunity to partner with European distributors, hospitals, and payers to broaden diagnostic access for AGHD and CGHD testing.

Pediatric CGHD Growth Leverage macimorelin's safety and adult success to target pediatric endocrinology networks for CGHD diagnosis, including collaboration on regulatory approvals and reimbursement in markets with unmet CGHD diagnostic needs.

Diagnostic Partnerships Build and scale partnerships with diagnostic labs, clinics, and endocrinology departments to accelerate uptake of macimorelin, supported by existing licensing and royalty arrangements in the US and potential Europe rest of world.

Monetize Non Core Explore monetization of non-strategic assets through licensing, divestitures, or collaborations to fund BD efforts and expand the macimorelin footprint and pipeline assets.

Strategic Growth Consider mergers, acquisitions, or co development partnerships with biotech players to broaden the portfolio, accelerate market access, and exploit synergies highlighted by recent corporate activity.